Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.83 USD | -0.10% | +4.81% | -27.92% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.92% | 1.49B | |
-14.13% | 11.53B | |
+45.76% | 3.31B | |
-35.86% | 2.11B | |
-18.27% | 2.05B | |
+18.02% | 1.02B | |
-3.49% | 741M | |
-31.42% | 426M | |
+26.64% | 372M | |
-47.55% | 374M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Veracyte : Touts Envisia Genomic Classier for Increased Accuracy in Diagnoses